In This Section

Spotlight on Clinical Trials

The deadline for clinical trial and late-breaking abstract submission was January 12, 2023. No more abstracts can be considered at this time.

ABSTRACT STATUS NOTIFICATIONS

Status notifications for clinical trial and late-breaking abstracts (submitted for the January 12, 2023 deadline) are scheduled to be sent out on February 16, 2023.

OPPORTUNITIES FOR CLINICAL TRIAL PRESENTERS

Numerous and unique oral presentation opportunities, including:
- Four Clinical Trials Plenary Sessions offering companion presentations explaining the science behind the presented trials
- Three Clinical Trials Minisymposia
Poster presentations
Opportunities to publish a manuscript in a high-impact AACR journal, including possible simultaneous publication with your abstract presentation
- Review the Simultaneous Journal Publication FAQ for more information
- Contact [email protected] with any questions
No restrictions on presenters if the presentation is CME-compliant

What to Submit

Any phase (first-in-human, I, II, III, or any combination) abstract from national or international clinical trials
- Biomarker studies:
  - If the abstract describes a predefined biomarker analysis that was part of the original trial design and trial data will be reported, then it may be submitted to a clinical trials category.
  - If the biomarker analysis was not part of the original trial design or was performed post hoc, then the abstract should be submitted to a Clinical Research category (CL01 Biomarkers) for the November 17, 2022, deadline (or as a late-breaking Clinical Research abstract on January 12, 2023, if the study is not complete by November 17, 2022).
Trials for solid tumors or blood cancers in adult or pediatric patients
Promising ongoing trials, or unique trial designs that have not yet yielded results. Select the Clinical Trials in Progress category (CT01) (Note that placeholder abstracts are not permitted for Trials in Progress.)

View trials in progress guidelines

Encore clinical trial presentations that have been presented solely in abstract form, including publication in conference proceedings. Submissions must include significant additional data from the previous presentation (as determined by the AACR Clinical Trials Committee).

View encore guidelines

When to Submit

Submit your completed or placeholder abstract(s) by the January 12, 2023, deadline for clinical trials abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the November 17, 2022, deadline.
A placeholder abstract may be submitted to one of the Clinical Trials Placeholder (PL) categories only if the trial is ongoing and final data are not available by January 12. In this case, a placeholder abstract with must be submitted by January 12. Final results and conclusions for placeholder abstracts are due by February 7, 2023.

View Clinical Trials Placeholder Guidelines

EMBARGO POLICY AND ONLINE PUBLICATION OF ABSTRACTS

In accordance with the AACR’s embargo policy, the content of abstracts must be kept confidential until they are made publicly available:

The titles and authors of the Clinical Trial and Late-Breaking Abstracts will be posted to the AACR Online Itinerary Planner no earlier than 4:30 p.m. U.S. ET on Tuesday, March 14, 2023. (Abstract Texts are Embargoed until 12:00 p.m. U.S. ET on Friday, April 14, 2023.)

The full text of the Clinical Trial and Late-Breaking Abstracts will be posted to the AACR Online Itinerary Planner and the Meeting App no earlier than 12:00 p.m. U.S. ET on Friday, April 14, 2023, except those abstracts that are selected for inclusion in the official AACR press program. Abstracts that are featured in the official AACR press program will be made publicly available at the date and time of presentation, either at the meeting or an official AACR press conference.

In previous years, abstracts accepted for presentation at the AACR Annual Meeting were published in an online-only Proceedings supplement to the AACR journal Cancer Research after the conclusion of the meeting. Beginning in 2023, the Proceedings supplement will be published prior to the meeting in two parts. Part 1 of the online Proceedings (regular abstracts) will be published on Friday, March 31, and Part 2 (clinical trials and late-breaking abstracts) will be published on Friday, April 14. Revised Proceedings supplements containing the full text of embargoed abstracts as well as any late change will be published in Cancer Research approximately one month after the meeting.

CLINICAL TRIALS (INCLUDING COMBINATION TRIALS) ABSTRACT CATEGORIES

CT01 Clinical Trials in Progress
- Phase I clinical trials in progress
- Phase II clinical trials in progress
- Phase III clinical trials in progress

CT02 COVID-19, Cancer, and Clinical Trials (See also COVID01: COVID-19 and Cancer)
- Clinical trials in progress
- Phase I
- Phase II
- Phase III
- Phase IV, observational, and expanded access

CT03 First-in-Human Phase I Clinical Trials

CT04 Phase I Adult Clinical Trials (See also ET07: Pharmacology, Pharmacogenetics, and Pharmacogenomics)

CT05 Phase II Adult Clinical Trials

CT06 Phase III Adult Clinical Trials

CT07 Phase I, II, or III Clinical Trials in the Elderly

CT08 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations

CT09 Phase I, II, or III Clinical Trials in Pediatric Cancer (See also CL08: Pediatric Cancer Clinical Investigations; TB06: Pediatric Cancer Basic Science)

PLACEHOLDER ABSTRACT CATEGORIES